Efficacy of recombinase polymerase amplification to diagnose trypanosoma cruzi infection in dogs with cardiac alterations from an endemic Area of Mexico

Matilde Jimenez-Coello, Thomas Shelite, Alejandro Castellanos, Omar Saldarriaga, Rocio Rivero, Antonio Ortega-Pacheco, Carlos Acevedo-Arcique, Karla Amaya-Guardia, Nisha Garg, Peter Melby, Bruno Travi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Chagas disease is a lingering Public Health problem in Latin America with ∼5.7 million people infected with Trypanosoma cruzi. Transmission is still taking place in most countries of the Americas, including the United States. Dogs are frequently infected with T. cruzi and its high infection prevalence is associated with increased risk of Chagas disease in humans. The city of Mérida in the Yucatan peninsula is endemic for Chagas disease and canines are frequently infected with T. cruzi. The objective of this study was to evaluate the performance of a qualitative point of care (POC) molecular test (RPA-LF, recombinase polymerase amplification-lateral flow) developed in our laboratory for identifying infected dogs. We used retrospective samples of dogs that came for consultation because of cardiac alterations and proved to be infected with T. cruzi as determined by enzyme-linked immunosorbent assay (ELISA), Western blot, and quantitative PCR (qPCR). The analytical sensitivity indicated that RPA-LF amplified T. cruzi DNA in samples containing almost equal to one to two parasites per reaction. Serial twofold dilutions of T. cruzi epimastigotes showed that the test had 95% (19/20) repeatability at concentrations of two parasites per reaction. The test showed no cross reactivity with human DNA or other protozoan parasites (Trypanosoma rangeli, Leishmania spp., and Plasmodium spp.). RPA-LF had the capacity to amplify all discrete typing units (DTUs I-VI) of T. cruzi that circulate in domestic or extradomestic environments. The RPA-LF had 93.2% (95% confidence interval 87.2-98.1) sensitivity and excellent agreement with qPCR used as gold standard (Cohen's Kappa test = 0.963). ELISA was positive in 96.6% (85/88) of dogs, which together with the molecular tests confirmed the frequent contact with infected triatomine bugs in the city of Mérida. These preliminary results on the diagnostic efficacy of the RPA-LF deserve further large-scale field testing of this POC test for T. cruzi infection in endemic areas.

Original languageEnglish (US)
Pages (from-to)417-423
Number of pages7
JournalVector-Borne and Zoonotic Diseases
Volume18
Issue number8
DOIs
StatePublished - Aug 1 2018

Fingerprint

Recombinases
Trypanosoma cruzi
Mexico
Dogs
Infection
Chagas Disease
Parasites
Trypanosoma rangeli
Enzyme-Linked Immunosorbent Assay
Point-of-Care Systems
Endemic Diseases
Polymerase Chain Reaction
Plasmodium
Latin America
Leishmania
Canidae
Referral and Consultation
Public Health
Western Blotting
Confidence Intervals

Keywords

  • Chagas disease
  • diagnosis
  • dogs
  • Mexico
  • molecular test
  • Trypanosoma cruzi

ASJC Scopus subject areas

  • Microbiology
  • Infectious Diseases
  • Virology

Cite this

Efficacy of recombinase polymerase amplification to diagnose trypanosoma cruzi infection in dogs with cardiac alterations from an endemic Area of Mexico. / Jimenez-Coello, Matilde; Shelite, Thomas; Castellanos, Alejandro; Saldarriaga, Omar; Rivero, Rocio; Ortega-Pacheco, Antonio; Acevedo-Arcique, Carlos; Amaya-Guardia, Karla; Garg, Nisha; Melby, Peter; Travi, Bruno.

In: Vector-Borne and Zoonotic Diseases, Vol. 18, No. 8, 01.08.2018, p. 417-423.

Research output: Contribution to journalArticle

@article{c203923a0cf2427cb24d16d346d404b3,
title = "Efficacy of recombinase polymerase amplification to diagnose trypanosoma cruzi infection in dogs with cardiac alterations from an endemic Area of Mexico",
abstract = "Chagas disease is a lingering Public Health problem in Latin America with ∼5.7 million people infected with Trypanosoma cruzi. Transmission is still taking place in most countries of the Americas, including the United States. Dogs are frequently infected with T. cruzi and its high infection prevalence is associated with increased risk of Chagas disease in humans. The city of M{\'e}rida in the Yucatan peninsula is endemic for Chagas disease and canines are frequently infected with T. cruzi. The objective of this study was to evaluate the performance of a qualitative point of care (POC) molecular test (RPA-LF, recombinase polymerase amplification-lateral flow) developed in our laboratory for identifying infected dogs. We used retrospective samples of dogs that came for consultation because of cardiac alterations and proved to be infected with T. cruzi as determined by enzyme-linked immunosorbent assay (ELISA), Western blot, and quantitative PCR (qPCR). The analytical sensitivity indicated that RPA-LF amplified T. cruzi DNA in samples containing almost equal to one to two parasites per reaction. Serial twofold dilutions of T. cruzi epimastigotes showed that the test had 95{\%} (19/20) repeatability at concentrations of two parasites per reaction. The test showed no cross reactivity with human DNA or other protozoan parasites (Trypanosoma rangeli, Leishmania spp., and Plasmodium spp.). RPA-LF had the capacity to amplify all discrete typing units (DTUs I-VI) of T. cruzi that circulate in domestic or extradomestic environments. The RPA-LF had 93.2{\%} (95{\%} confidence interval 87.2-98.1) sensitivity and excellent agreement with qPCR used as gold standard (Cohen's Kappa test = 0.963). ELISA was positive in 96.6{\%} (85/88) of dogs, which together with the molecular tests confirmed the frequent contact with infected triatomine bugs in the city of M{\'e}rida. These preliminary results on the diagnostic efficacy of the RPA-LF deserve further large-scale field testing of this POC test for T. cruzi infection in endemic areas.",
keywords = "Chagas disease, diagnosis, dogs, Mexico, molecular test, Trypanosoma cruzi",
author = "Matilde Jimenez-Coello and Thomas Shelite and Alejandro Castellanos and Omar Saldarriaga and Rocio Rivero and Antonio Ortega-Pacheco and Carlos Acevedo-Arcique and Karla Amaya-Guardia and Nisha Garg and Peter Melby and Bruno Travi",
year = "2018",
month = "8",
day = "1",
doi = "10.1089/vbz.2017.2258",
language = "English (US)",
volume = "18",
pages = "417--423",
journal = "Vector-Borne and Zoonotic Diseases",
issn = "1530-3667",
publisher = "Mary Ann Liebert Inc.",
number = "8",

}

TY - JOUR

T1 - Efficacy of recombinase polymerase amplification to diagnose trypanosoma cruzi infection in dogs with cardiac alterations from an endemic Area of Mexico

AU - Jimenez-Coello, Matilde

AU - Shelite, Thomas

AU - Castellanos, Alejandro

AU - Saldarriaga, Omar

AU - Rivero, Rocio

AU - Ortega-Pacheco, Antonio

AU - Acevedo-Arcique, Carlos

AU - Amaya-Guardia, Karla

AU - Garg, Nisha

AU - Melby, Peter

AU - Travi, Bruno

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Chagas disease is a lingering Public Health problem in Latin America with ∼5.7 million people infected with Trypanosoma cruzi. Transmission is still taking place in most countries of the Americas, including the United States. Dogs are frequently infected with T. cruzi and its high infection prevalence is associated with increased risk of Chagas disease in humans. The city of Mérida in the Yucatan peninsula is endemic for Chagas disease and canines are frequently infected with T. cruzi. The objective of this study was to evaluate the performance of a qualitative point of care (POC) molecular test (RPA-LF, recombinase polymerase amplification-lateral flow) developed in our laboratory for identifying infected dogs. We used retrospective samples of dogs that came for consultation because of cardiac alterations and proved to be infected with T. cruzi as determined by enzyme-linked immunosorbent assay (ELISA), Western blot, and quantitative PCR (qPCR). The analytical sensitivity indicated that RPA-LF amplified T. cruzi DNA in samples containing almost equal to one to two parasites per reaction. Serial twofold dilutions of T. cruzi epimastigotes showed that the test had 95% (19/20) repeatability at concentrations of two parasites per reaction. The test showed no cross reactivity with human DNA or other protozoan parasites (Trypanosoma rangeli, Leishmania spp., and Plasmodium spp.). RPA-LF had the capacity to amplify all discrete typing units (DTUs I-VI) of T. cruzi that circulate in domestic or extradomestic environments. The RPA-LF had 93.2% (95% confidence interval 87.2-98.1) sensitivity and excellent agreement with qPCR used as gold standard (Cohen's Kappa test = 0.963). ELISA was positive in 96.6% (85/88) of dogs, which together with the molecular tests confirmed the frequent contact with infected triatomine bugs in the city of Mérida. These preliminary results on the diagnostic efficacy of the RPA-LF deserve further large-scale field testing of this POC test for T. cruzi infection in endemic areas.

AB - Chagas disease is a lingering Public Health problem in Latin America with ∼5.7 million people infected with Trypanosoma cruzi. Transmission is still taking place in most countries of the Americas, including the United States. Dogs are frequently infected with T. cruzi and its high infection prevalence is associated with increased risk of Chagas disease in humans. The city of Mérida in the Yucatan peninsula is endemic for Chagas disease and canines are frequently infected with T. cruzi. The objective of this study was to evaluate the performance of a qualitative point of care (POC) molecular test (RPA-LF, recombinase polymerase amplification-lateral flow) developed in our laboratory for identifying infected dogs. We used retrospective samples of dogs that came for consultation because of cardiac alterations and proved to be infected with T. cruzi as determined by enzyme-linked immunosorbent assay (ELISA), Western blot, and quantitative PCR (qPCR). The analytical sensitivity indicated that RPA-LF amplified T. cruzi DNA in samples containing almost equal to one to two parasites per reaction. Serial twofold dilutions of T. cruzi epimastigotes showed that the test had 95% (19/20) repeatability at concentrations of two parasites per reaction. The test showed no cross reactivity with human DNA or other protozoan parasites (Trypanosoma rangeli, Leishmania spp., and Plasmodium spp.). RPA-LF had the capacity to amplify all discrete typing units (DTUs I-VI) of T. cruzi that circulate in domestic or extradomestic environments. The RPA-LF had 93.2% (95% confidence interval 87.2-98.1) sensitivity and excellent agreement with qPCR used as gold standard (Cohen's Kappa test = 0.963). ELISA was positive in 96.6% (85/88) of dogs, which together with the molecular tests confirmed the frequent contact with infected triatomine bugs in the city of Mérida. These preliminary results on the diagnostic efficacy of the RPA-LF deserve further large-scale field testing of this POC test for T. cruzi infection in endemic areas.

KW - Chagas disease

KW - diagnosis

KW - dogs

KW - Mexico

KW - molecular test

KW - Trypanosoma cruzi

UR - http://www.scopus.com/inward/record.url?scp=85050850589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050850589&partnerID=8YFLogxK

U2 - 10.1089/vbz.2017.2258

DO - 10.1089/vbz.2017.2258

M3 - Article

VL - 18

SP - 417

EP - 423

JO - Vector-Borne and Zoonotic Diseases

JF - Vector-Borne and Zoonotic Diseases

SN - 1530-3667

IS - 8

ER -